RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00050348.xml
PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(02): 241-250
DOI: 10.1055/s-0042-1760320
DOI: 10.1055/s-0042-1760320
Review Article
Imaging Recommendations for Diagnosis, Staging, and Management of Hepatic and Biliary Tract Cancer
Abstract
Major hepatobiliary cancers include hepatocellular carcinoma, gallbladder carcinoma, and cholangiocarcinoma. There are multiple guidelines and recommendations for the imaging evaluation of these cancers. This article reviews and summarizes principles and recommendations of imaging in hepatobiliary cancers. The cross-sectional imaging protocol is similar among these lesions and is discussed at first followed by the separate discussion of each cancer.
Keywords
cholangiocarcinoma - computed tomography - gallbladder carcinoma - hepatocellular carcinoma - magnetic resonance imagingPublikationsverlauf
Artikel online veröffentlicht:
01. März 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Acharya SK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol 2014; 4 (Suppl. 03) S27-S33
- 2 Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2013; 1 (06) 180-182
- 3 Asim M, Sarma MP, Kar P. Etiological and molecular profile of hepatocellular cancer from India. Int J Cancer 2013; 133 (02) 437-445
- 4 European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
- 5 Paul SB, Sreenivas V, Gulati MS. et al. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India. Indian J Gastroenterol 2007; 26 (06) 274-278
- 6 Yeole BB. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev 2008; 9 (01) 97-100
- 7 Dikshit R, Gupta PC, Ramasundarahettige C. et al; Million Death Study Collaborators. Cancer mortality in India: a nationally representative survey. Lancet 2012; 379 (9828): 1807-1816
- 8 Singal AG, Zhang E, Narasimman M. et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a systematic review and meta-analysis. J Hepatol 2022; 77 (01) 128-139
- 9 Tzartzeva K, Obi J, Rich NE. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018; 154 (06) 1706-1718.e1
- 10 Benson AB, D'Angelica MI, Abbott DE. et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19 (05) 541-565
- 11 American College of Radiology. Ultrasound LI-RADS v2017. Accessed December 23, 2022 https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/LI-RADS-Ultrasound-v2017
- 12 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
- 13 American College of Radiology. Liver imaging reporting and data system. Accessed December 23, 2022. https://www.acr.org/Quality-Safety/Resources/LIRADS
- 14 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021; 74 (05) 2342-2352
- 15 Mazzaferro V, Citterio D, Bhoori S. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21 (07) 947-956
- 16 Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol 2020; 72 (02) 288-306
- 17 Gordan JD, Kennedy EB, Abou-Alfa GK. et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol 2020; 38 (36) 4317-4345
- 18 Akinyemiju T, Abera S, Ahmed M. et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3 (12) 1683-1691
- 19 Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012; 6 (02) 172-187
- 20 Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol 2019; 5 (02) 93-102
- 21 Dutta U, Bush N, Kalsi D, Popli P, Kapoor VK. Epidemiology of gallbladder cancer in India. Linchuang Zhongliuxue Zazhi 2019; 8 (04) 33
- 22 Rathanaswamy S, Misra S, Kumar V. et al. Incidentally detected gallbladder cancer- the controversies and algorithmic approach to management. Indian J Surg 2012; 74 (03) 248-254
- 23 Rodríguez-Fernández A, Gómez-Río M, Medina-Benítez A. et al. Application of modern imaging methods in diagnosis of gallbladder cancer. J Surg Oncol 2006; 93 (08) 650-664
- 24 Akiba J, Nakashima O, Hattori S. et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013; 37 (04) 496-505
- 25 DeOliveira ML, Cunningham SC, Cameron JL. et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245 (05) 755-762
- 26 Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 2007; 19 (08) 615-617
- 27 Chatterjee A, Lopes Vendrami C, Nikolaidis P. et al. Uncommon intraluminal tumors of the gallbladder and biliary tract: spectrum of imaging appearances. Radiographics 2019; 39 (02) 388-412
- 28 Ainechi S, Lee H. Updates on precancerous lesions of the biliary tract: biliary precancerous lesion. Arch Pathol Lab Med 2016; 140 (11) 1285-1289
- 29 Lamarca A, Barriuso J, Chander A. et al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. J Hepatol 2019; 71 (01) 115-129
- 30 Ahn JC, Yang JD. Screening indications and treatments for cholangiocarcinoma. Curr Hepatol Rep 2019; 18: 408-416
- 31 Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 2003; 181 (03) 819-827
- 32 Kang Y, Lee JM, Kim SH, Han JK, Choi BI. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 2012; 264 (03) 751-760
- 33 Watkinson AF, Adam A. Interventional Radiology: A Practical Guide. New York, USA:: Radcliffe Publishing; 1996
- 34 Jung G-S, Huh J-D, Lee SU, Han BH, Chang H-K, Cho YD. Bile duct: analysis of percutaneous transluminal forceps biopsy in 130 patients suspected of having malignant biliary obstruction. Radiology 2002; 224 (03) 725-730
- 35 Ahrar K, Gupta S. Percutaneous Image-Guided Biopsy. New York, USA:: Springer Science & Business Media; 2013
- 36 Brugge WR, De Witt J, Klapman JB. et al. Techniques for cytologic sampling of pancreatic and bile duct lesions: the Papanicolaou Society of Cytopathology guidelines. Cytojournal 2014; 11 (Suppl. 01) 2
- 37 Madhusudhan KS, Gamanagatti S, Gupta AK. Imaging and interventions in hilar cholangiocarcinoma: a review. World J Radiol 2015; 7 (02) 28-44
- 38 Nimura Y, Kamiya J, Kondo S. et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000; 7 (02) 155-162